Baclofen in the treatment of trigeminal neuralgia: Double‐blind study and long‐term follow‐up

Fromm, Gerhard H.; Terrence, Christopher F.; Chattha, Amrik S.

doi:10.1002/ana.410150306

Cited by 331 publications

(109 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other drugs have each been studied in single trials: baclofen (40 to 80 mg a day) was superior to placebo in reducing the number of painful paroxysms (Class II) 30 ; lamotrigine (400 mg a day) was effective as add-on therapy on a composite index of efficacy (Class II) 31 ; pimozide (4 to 12 mg a day) was more effective than CBZ (Class II) 35 ; and tocainide (12 mg a day) was as effective as CBZ (Class III). 34 Tizanidine was better than placebo in a small study but its effect diminished within 1 to 3 months (Class III).…”

Section: For Patients With Classic Tn Does High-resolution Mri Accurmentioning

confidence: 99%

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Cruccu²,

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: For Patients With Classic Tn Does High-resolution Mri Accurmentioning

confidence: 99%

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Cruccu²,

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Baclofen selectively activates GABA-B receptors pre-and postsynaptically, leading to a decrease in excitatory transmission and an increase in inhibition, resulting in marked segmental inhibition. In human studies, open (220) and controlled trials (221) have found baclofen to exhibit an analgesic effect in trigeminal neuralgia. Uncontrolled reports have supported an effect in glossopharyngeal and vagoglossopharyngeal neuralgia, and episodic and allodynic pain in some patients with opthalmic postherpetic neuralgia (220).…”

Section: Physical Dependencementioning

confidence: 99%

The Pharmacotherapy of Chronic Pain: A Review

Lynch

Watson

2006

Pain Research and Management

100

View full text Add to dashboard Cite

The past two decades have contributed a large body of preclinical work that has assisted in our understanding of the underlying pathophysiological mechanisms that cause chronic pain. In this context, it has been recognized that effective treatment of pain is a priority and that treatment often involves the use of one or a combination of agents with analgesic action. The current review presents an evidence-based approach to the pharmacotherapy of chronic pain. Medline searches were done for all agents used as conventional treatment in chronic pain. Published papers up to June 2005 were included. The search strategy included randomized, controlled trials, and where available, systematic reviews and meta-analyses. Further references were found in reference sections of papers located using the above search strategy. Agents for which there were no controlled trials supporting efficacy in treatment of chronic pain were not included in the present review, except in cases where preclinical science was compelling, or where initial human work has been positive and where it was thought the reader would be interested in the scientific evidence to date.Key Words: Anticonvulsants; Antidepressants; Cannabinoids; Chronic pain; Opioids; Pharmacotherapy; Topical analgesics La pharmacothérapie de la douleur chronique : Une analyse Les deux dernières décennies ont contribué à un vaste ensemble de travaux précliniques qui nous ont permis de mieux comprendre les mécanismes physiopathologiques sous-jacents responsables de la douleur chronique. Dans ce contexte, il est admis que le traitement efficace de la douleur est une priorité et qu'il exige souvent le recours à un agent ou à une association d'agents ayant une action analgésique. La présente analyse présente une démarche probante de la pharmacothérapie de la douleur chronique. Des recherches dans Medline ont été effectuées sur tous les agents utilisés pour le traitement classique de la douleur chronique. Les articles publiés jusqu'en juin 2005 ont été inclus. La stratégie de recherche incluait les essais aléatoires et contrôlés et, si elles étaient disponibles, les analyses systématiques et les méta-analyses. D'autres références ont été obtenues dans la partie des références des articles trouvés à l'aide de la stratégie de recherche précédente. Les agents dont aucun essai contrôlé n'étayait l'efficacité pour le traitement de la douleur chronique étaient exclus de la présente analyse, sauf si les données scientifiques précliniques étaient convaincantes, si les travaux humains initiaux étaient positifs ou si on pensait que les données scientifiques colligées jusque-là étaient intéressantes pour le lecteur.

show abstract

“…Amédia do escore de qualidade foi 4 (variando de 3 a 5). Os motivos de exclusão dos demais trabalhos foram: ensaio clínico não aleatório [13][14][15][16][17][18][19][20][21][22][23][24] , provavelmente não aleatório [25][26][27] , dor neuropática não especificada 28,29 , e estudos não disponíveis no Brasil ou sequer selecionados em revisões recentes sobre o assunto [30][31][32][33] . Dos artigos incluídos nesta revisão, seis compararam a carbamazepina ao placebo [34][35][36][37][38][39] (Tabela I), os demais compararam a lamotrigina, a tocainida, o topiramato, o dextrometafano, a pimozida, o cloridrato de proparacaína e a tizanidina ao placebo ou ao tratamento ativo (Tabela II).…”

Section: Resultsunclassified

Tratamento famacológico da neuralgia do trigêmeo: revisão sistemática e metanálise

Alves¹,

Azevedo²,

Carvalho³

2004

Rev. Bras. Anestesiol.

View full text Add to dashboard Cite

RESUMO (Colaboração Cochrane, 2003). (Cochrane Collaboration, 2003). RESULTADOS: Os resultados da metanálise sugerem que a carbamazepina é mais eficaz que o placebo. Em três estudos controlados comparando a lamotrigina, o topiramato e o cloridrato de proparacaína ao placebo, somente a lamotrigina mostrou-se superior a ele. O dextrometafano foi comparado ao lorazepam em baixas doses, havendo aumento da dor com o u s o d a q u e l e f á r m a c o . Tr ê s e s t u d o s c o m pa r a r a m a carbamazepina com a tizanidina, a tocainida e a pimozida U n i t e r m o s : D O R , C r ô n i c a : n e u r a l g i a d o t r i g ê m e o ; TERAPÊUTICA, Farmacológica SUMMARY RESULTS: Metanalisys results suggest that carbamazepine is more efficient than placebo. In three controlled studies comparing lamotrigine, topiramate and 0.5% proparacaine hydrochlor i d e , o n l y l a m o t r i g i n e wa s s u p e r i o r t o p l a c e b o . Dextromethorphan was compared to low-dose lorazepam

show abstract

Baclofen in the treatment of trigeminal neuralgia: Double‐blind study and long‐term follow‐up

Cited by 331 publications

References 24 publications

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review)

The Pharmacotherapy of Chronic Pain: A Review

Tratamento famacológico da neuralgia do trigêmeo: revisão sistemática e metanálise

Contact Info

Product

Resources

About